Literature DB >> 17822675

Corticotropin-releasing factor family and its receptors: tumor therapeutic targets?

Juejin Wang1, Shengnan Li.   

Abstract

Urocortin (UCN) and corticotropin-releasing factor (CRF) are members of CRF family. Though CRF is mainly distributed in central nervous system (CNS), UCN has been reported to play biologically diverse roles in several systems such as cardiovascular, respiratory, digestive, reproductive, stress, immunologic system, etc. UCN and CRF bind to two known receptors, CRFR1 and CRFR2, to function. Both CRF receptors are distributed in CNS and periphery tissues, and their expression in cancer tissues has been reported. Now there are many documents indicating UCN/CRF play an important role in the regulation of carcinogenesis. There is also evidence indicating UCN/CRF have anticancer effects via CRFRs. This paper will review the effects of CRF family in cancers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17822675     DOI: 10.1016/j.bbrc.2007.08.014

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  The corticotropin releasing factor system in cancer: expression and pathophysiological implications.

Authors:  Athina Kaprara; Kalliopi Pazaitou-Panayiotou; Alexandros Kortsaris; Ekaterini Chatzaki
Journal:  Cell Mol Life Sci       Date:  2010-02-09       Impact factor: 9.261

2.  An intronic polymorphism in the corticotropin-releasing hormone receptor 2 gene increases susceptibility to HBV-related hepatocellular carcinoma in Chinese population.

Authors:  Xing Gu; Peng Qi; Feiguo Zhou; Qiang Ji; Hao Wang; Tonghai Dou; Yunpeng Zhao; Chunfang Gao
Journal:  Hum Genet       Date:  2009-10-08       Impact factor: 4.132

3.  Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation.

Authors:  Zhengrong Hao; Yan Huang; Jake Cleman; Ion S Jovin; Wylie W Vale; Tracy L Bale; Frank J Giordano
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-28       Impact factor: 11.205

4.  Hypermethylation of Corticotropin Releasing Hormone Receptor-2 Gene in Ulcerative Colitis Associated Colorectal Cancer.

Authors:  Masayoshi Kobayashi; Nagahide Matsubara; Yutaka Nakachi; Yasushi Okazaki; Motoi Uchino; Hiroki Ikeuchi; Jihyng Song; Kei Kimura; Michiko Yasuhara; Akihito Babaya; Tomoki Yamano; Masataka Ikeda; Hiroki Nishikawa; Ikuo Matsuda; Seiichi Hirota; Naohiro Tomita
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

5.  Corticotropin Releasing Factor promotes breast cancer cell motility and invasiveness.

Authors:  Ariadne Androulidaki; Erini Dermitzaki; Maria Venihaki; Effie Karagianni; Olga Rassouli; Erini Andreakou; Christos Stournaras; Andrew N Margioris; Christos Tsatsanis
Journal:  Mol Cancer       Date:  2009-06-02       Impact factor: 27.401

Review 6.  Current and future G protein-coupled receptor signaling targets for heart failure therapy.

Authors:  Ashley Siryk-Bathgate; Samalia Dabul; Anastasios Lymperopoulos
Journal:  Drug Des Devel Ther       Date:  2013-10-11       Impact factor: 4.162

7.  Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation.

Authors:  Hossein Tezval; Stefanie Jurk; Farahnaz Atschekzei; Jan U Becker; Olaf Jahn; Jürgen Serth; Markus A Kuczyk
Journal:  World J Urol       Date:  2009-12       Impact factor: 4.226

8.  Reduced mRNA expression level of corticotropin-releasing hormone-binding protein is associated with aggressive human kidney cancer.

Authors:  Hossein Tezval; Faranaz Atschekzei; Inga Peters; Sandra Waalkes; Jörg Hennenlotter; Arnulf Stenzl; Jan U Becker; Axel S Merseburger; Markus A Kuczyk; Jürgen Serth
Journal:  BMC Cancer       Date:  2013-04-22       Impact factor: 4.430

9.  CRF2 signaling is a novel regulator of cellular adhesion and migration in colorectal cancer cells.

Authors:  Benjamin Ducarouge; Marjolaine Pelissier-Rota; Michèle Lainé; Nadine Cristina; Yvan Vachez; Jean-Yves Scoazec; Bruno Bonaz; Muriel Jacquier-Sarlin
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.